SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol 2004; 18: 70522.
  • 2
    Imrich R, Bosak V, Rovensky J. Polymyalgia rheumatica and temporal arteritis: the endocrine relations and the pathogenesis [review]. Endocr Regul 2006; 40: 839.
  • 3
    Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36: 128694.
  • 4
    Meliconi R, Pulsatelli L, Dolzani P, Boiardi L, Macchioni P, Salvarani C, et al. Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum 2000; 43: 247280.
  • 5
    Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005; 53: 338.
  • 6
    Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005; 32: 6573.
  • 7
    Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999; 159: 57784.
  • 8
    Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43: 10418.
  • 9
    Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ, et al. Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004; 43: 294301.
  • 10
    Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15: 4358.
  • 11
    Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984; 13: 3228.
  • 12
    Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994; 121: 48491.
  • 13
    Ellingsen T, Elling P, Olson A, Elling H, Baandrup U, Matsushima K, et al. Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica. Ann Rheum Dis 2000; 59: 77580.
  • 14
    Uddhammar A, Sundqvist KG, Ellis B, Rantapaa-Dahlqvist S. Cytokines and adhesion molecules in patients with polymyalgia rheumatica. Br J Rheumatol 1998; 37: 7669.
  • 15
    Cutolo M, Montecucco CM, Cavagna L, Caporali R, Capellino S, Montagna P, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 2006; 65: 143843.
  • 16
    Pulsatelli L, Meliconi R, Boiardi L, Macchioni P, Salvarani C, Facchini A. Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica. Clin Exp Rheumatol 1998; 16: 2638.
  • 17
    Cid MC, Hoffman MP, Hernandez-Rodriguez J, Segarra M, Elkin M, Sanchez M, et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology (Oxford) 2006; 45: 135663.
  • 18
    Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 62130.
  • 19
    Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007; 146: 6319.
  • 20
    Luqmani R. Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward? Ann Intern Med 2007; 146: 6746.
  • 21
    Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, et al. Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 2006; 33: 7038.
  • 22
    Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Mattey DL, Amoli MM, et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002; 20: 17984.
  • 23
    Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999; 26: 132632.
  • 24
    Amoli MM, Shelley E, Mattey DL, Garcia-Porrua C, Thomson W, Hajeer AH, et al. Intercellular adhesion molecule-1 gene polymorphisms in isolated polymyalgia rheumatica. J Rheumatol 2002; 29: 5024.
  • 25
    Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 1998; 82: 18606.
  • 26
    Sadeghi M, Daniel V, Naujokat C, Mehrabi A, Opelz G. Association of high pretransplant sIL-6R plasma levels with acute tubular necrosis in kidney graft recipients. Transplantation 2006; 81: 171624.
  • 27
    Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2002; 87: 494651.
  • 28
    Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 1999; 189: 599604.
  • 29
    Marta RF, Goette NP, Lev PR, Chazarreta CD, Pirola CJ, Molinas FC. Normal platelets possess the soluble form of IL-6 receptor. Cytokine 2005; 29: 137.
  • 30
    Modur V, Li Y, Zimmerman GA, Prescott SM, McIntyre TM. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor α. J Clin Invest 1997; 100: 27526.
  • 31
    Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6: 31525.
  • 32
    Uddhammar A, Rantapaa-Dahlqvist S, Nilsson TK. Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica. Clin Rheumatol 1992; 11: 2115.
  • 33
    Cid MC, Monteagudo J, Oristrell J, Vilaseca J, Pallares L, Cervera R, et al. Von Willebrand factor in the outcome of temporal arteritis. Ann Rheum Dis 1996; 55: 92730.
  • 34
    Uddhammar A, Rantapaa-Dahlqvist S, Nilsson TK. Long-term follow up of von Willebrand factor and plasminogen activator inhibitor-1 in patients with polymyalgia rheumatica [letter]. Ann Rheum Dis 1997; 56: 6989.
  • 35
    Meliconi R, Pulsatelli L, Melchiorri C, Frizziero L, Salvarani C, Macchioni P, et al. Synovial expression of cell adhesion molecules in polymyalgia rheumatica. Clin Exp Immunol 1997; 107: 494500.
  • 36
    Coyne CP, Howell T III, Baravick J, Baravick E, Willetto C, Fenwick BW. Biochemical alteration of membrane-associated IL-6 RI (80-kDa) in adherent macrophages and vascular endothelium. Mol Immunol 2001; 38: 34757.
  • 37
    Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005; 65: 10794800.
  • 38
    Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4: 38691.
  • 39
    Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 2006; 195: 17383.